Apoptosis and Cancer Progression: Balancing Tumor Suppression and Disease Advancement

Abstract

Background: Apoptosis is a tightly regulated form of programmed cell death that is essential for tissue homeostasis, normal development, and tumour suppression. Although defective apoptotic signalling is a hallmark of cancer, accumulating evidence indicates that apoptosis may also paradoxically promote tumour progression through its effects on the tumour microenvironment (TME), giving rise to the concept of the "apoptosis paradox." Objectives: To critically review the dual role of apoptosis in cancer progression, with particular emphasis on its immunomodulatory, regenerative, and pro-tumorigenic functions within the TME, and to discuss the therapeutic implications of targeting apoptosis-associated pathways. Methods: A comprehensive narrative review of the contemporary literature was conducted using peer-reviewed studies addressing the molecular mechanisms of apoptosis, apoptosis-mediated remodelling of the TME, immune regulation, autophagy, angiogenesis, metastasis, therapeutic resistance, and emerging apoptosis-targeted cancer therapies. Results: Current evidence demonstrates that, beyond eliminating damaged or transformed cells, apoptotic tumour cells actively influence the TME by releasing bioactive mediators that regulate immune responses, promote pro-tumorigenic macrophage polarization, stimulate angiogenesis and tissue regeneration, and facilitate tumour growth, metastatic dissemination, and resistance to therapy. Furthermore, the intricate interplay between apoptosis, autophagy, and immune signalling highlights the context-dependent nature of programmed cell death in cancer biology, challenging the traditional view of apoptosis as solely tumour suppressive. Conclusions: Apoptosis exhibits a dualistic role in cancer, functioning as both a tumour-suppressive and tumour-promoting process depending on the biological context. A deeper understanding of apoptosis-mediated interactions within the TME may uncover novel therapeutic targets and support the development of precision-based strategies that improve treatment efficacy and clinical outcomes in patients with cancer.